Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,643,832
  • Shares Outstanding, K 2,521,671
  • Annual Sales, $ 45,310 M
  • Annual Income, $ 7,081 M
  • 60-Month Beta 0.56
  • Price/Sales 2.56
  • Price/Cash Flow 8.48
  • Price/Book 1.53
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 22.80% ( -1.32%)
  • Historical Volatility 17.64%
  • IV Percentile 2%
  • IV Rank 4.90%
  • IV High 41.45% on 10/11/22
  • IV Low 21.84% on 01/13/23
  • Put/Call Vol Ratio 0.16
  • Today's Volume 262
  • Volume Avg (30-Day) 957
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 28,090
  • Open Int (30-Day) 37,095

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate 1.01
  • Number of Estimates 3
  • High Estimate 1.02
  • Low Estimate 1.01
  • Prior Year 1.09
  • Growth Rate Est. (year over year) -7.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.32 +1.19%
on 02/06/23
49.93 -8.15%
on 01/17/23
-2.28 (-4.74%)
since 01/06/23
3-Month
42.23 +8.60%
on 11/11/22
49.93 -8.15%
on 01/17/23
+2.24 (+5.14%)
since 11/04/22
52-Week
36.91 +24.25%
on 09/26/22
58.10 -21.07%
on 04/11/22
-6.22 (-11.94%)
since 02/04/22

Most Recent Stories

More News
Sanofi (SNY) Q4 2022 Earnings Call Transcript

SNY earnings call for the period ending December 31, 2022.

SNY : 45.86 (-0.35%)
Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

SNY : 45.86 (-0.35%)
GSK : 35.34 (+1.46%)
NVO : 138.07 (+0.94%)
GILD : 86.36 (+2.20%)
Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline

Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.

REGN : 780.86 (-0.29%)
SNY : 45.86 (-0.35%)
RHHBY : 38.3500 (+0.63%)
BAYRY : 15.6600 (+2.22%)
Sanofi (SNY) Q4 Earnings Miss Estimates, Vaccine Sales Weak

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. Higher sales of Dupixent and other specialty medicines were offset by a decline in vaccine sales.

REGN : 780.86 (-0.29%)
SNY : 45.86 (-0.35%)
RHHBY : 38.3500 (+0.63%)
NVO : 138.07 (+0.94%)
Pharma Stock Roundup: MRK, LLY, PFE Q4 Results, J&J's Loss in Talc Lawsuits

Pfizer (PFE), Merck (MRK), Eli Lilly (LLY) and others report fourth-quarter results. An appeals court dismisses J&J's (JNJ) bankruptcy filing related to its talc lawsuits.

SNY : 45.86 (-0.35%)
JNJ : 163.36 (-0.76%)
PFE : 43.76 (-0.68%)
MRK : 104.03 (+1.06%)
LLY : 337.66 (-0.42%)
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales

Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.

SNY : 45.86 (-0.35%)
BMY : 74.53 (+0.11%)
PFE : 43.76 (-0.68%)
NVO : 138.07 (+0.94%)
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal

Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.

REGN : 780.86 (-0.29%)
SNY : 45.86 (-0.35%)
RHHBY : 38.3500 (+0.63%)
NVO : 138.07 (+0.94%)
Merck (MRK) Beats on Q4 Earnings & Sales, 2023 View Disappoints

Merck (MRK) beats Q4 estimates for earnings and sales. Its 2023 profit guidance disappoints. Stock declines in pre-market.

SNY : 45.86 (-0.35%)
AZN : 63.52 (+0.13%)
NVO : 138.07 (+0.94%)
MRK : 104.03 (+1.06%)
Is a Surprise Coming for Sanofi (SNY) This Earnings Season?

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

SNY : 45.86 (-0.35%)
Novo Nordisk (NVO) Q4 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.

SNY : 45.86 (-0.35%)
NVO : 138.07 (+0.94%)
CABA : 12.37 (+0.49%)
LIAN : 2.24 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 46.82
2nd Resistance Point 46.41
1st Resistance Point 46.13
Last Price 45.86
1st Support Level 45.45
2nd Support Level 45.04
3rd Support Level 44.77

See More

52-Week High 58.10
Fibonacci 61.8% 50.01
Fibonacci 50% 47.50
Last Price 45.86
Fibonacci 38.2% 45.00
52-Week Low 36.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar